The use of triacetyloleandomycin in skin and soft tissue infections: results of a New Zealand general-practitioner multi-centre trial.
Fifty-one New Zealand general practitioners observed the treatment of 137 cases of skin and soft tissue infections with triacetyloleandomycin (TAO, Pfizer) over a five-month period. Nearly a third of these lesions occurred in children aged 10 years or less. "Excellent" or "good" results in 129 cases (94.2 percent) confirmed triacetyloleandomycin to be generally effective in these conditions. Twice-daily (12-hourly) oral administration proved as effective as more frequent dosage regimens and no major side-effects were encountered. Twenty cases with associated minor surgery are discussed separately.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001419:Bacteria / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D005194:Family Practice; D006801:Humans; D007223:Infant; D007239:Infections / Q000188:drug therapy*; D008875:Middle Aged; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology; D014217:Troleandomycin / Q000009:adverse effects / Q000627:therapeutic use*
D014217:Troleandomycin